[ 1 ] Appella E, et al.J Biol.Chem.1987, 262:4437

[ 2 ] Patthy L.Cell.1985, 41:657

[ 3 ] 李节, 邱平.尿激酶与肿瘤转移[J].国外医学分子生物学分册, 1994, 16 (1) :26~28 link1

[ 4 ] Hudson M A, McReynold L M.Urokinase (u-PA) and u-PA receptor:Madulation of in vitro invasiveness of humanbladder cancer cell lines[J].Adv Exp Med Biol, 1999, 462:399~412

[ 5 ] 王丽石, 朱运松.uPA基因表达调控研究进展[J].医学分子生物学杂志, 2004, 1 (4) :235~238 link1

[ 6 ] Puricelli, Proiettii C J, Labriola L, et al.Heregulijn inhibitsproliferation via ERKs and phosphatidyl-inositol 3-kinaseactiration but regulates urokinase plasminogen activatorindepently of these:Pathways in metastatic mammary tumorcells[J].Int J Cancer, 2002, 100 (6) :642~53

[ 7 ] 唐辉滨, 朱运松, 宋后燕.肿瘤浸润、转移与uPA和PAI-1关系[J].国外医学肿瘤学分册, 1995, 2 (22) :10~13 link1

[ 8 ] Jane L F, Petter S M, Monique L H, et al.Theexpression of the urokinase plasminogen activator system inmetastatic murine osteosarcoma[J].Clinical CancerResearch, 2001, 7:1654~1660

[ 9 ] Saluda-Geogul A, Pytel J, Olborski B, et al.Atigenlevels of urokinase type plasminogen activator and itsinhibitors in primary breast cancer[J].Z Naturforseh, 2002, 57:366~371

[10] Seddighzadeh M, Steineek G, Larsson P, et al.Expression of uPA and uPAR is as with the clinical courseof orinary bladder neoplasms[J].Int J Cancer, 2002, 99:721~726

[11] 陈贵安, 冯强, 张丽珠, 等.人子宫内膜纤蛋白溶酶元激活因子及其抑制因子的分布与调控[J].生理学报, 1992, 44 (5) :502~509 link1

[12] Casslen B, Astedt B.Fibrinolytic activity of human uterinefluid[J].Acta Obstet, Gynecol, Scand, 1981, 60:55~58

[13] Casslen B, Andersson A, Nilsson I M, Astedt B.Hormonal regulation of the release of plasminogenactivators and of a specific activator inhibitor fromendometrial tissue in culture[J].Procsoc Exp Biol Med, 1986, 192:419~424

[14] Schatz F, Aigner S, Papp C, et al.Plasminogen activatoractivity during decidualization of human endometrialstromal cells is regulated by plasminogen activatorinhibitor1[J].J Clin Endocrinol Metab, 1995, 80:2504~2510

[15] Casslen B, Nordengren J, Gustavsson B, et al.Progestinstimulates degradation of urokinase plasminogen activator inendometrial stromal cells by increasing its inhibitor andsurface expression of the uPA receptor[J].J ClinEndocrinol Metab, 1995, 80:2776~2784

[16] 吴翠娇, 史玉霞.尿激酶型纤溶酶原激活剂系统在子宫内膜腺癌中的表达[J].Central China Journal, 2001, 25 (4) :190~191 link1

[17] Taponew F, Curcio C, et al.Expression and prognosticsignificance of urokinase and plasminogen activatorinhibitor type-1 in endometrial hyperplasia and cancer[J].J Exp Clin Cancer Res, 2001, 20 (2) :239~46

[18] Glesson N, Gonsalves R, Bonnar J.The uPA and PAI-2in endometrial Cancer[J].Gynecol Oncol, 1992, 97:58~61

[19] Krohler U, Hiller K, et al.Tumor-Associated ProteolyticFactors uPA and PAI-1 in Endometrial Carcinoma[J].Gynecologic On Cology, 1997, 66:268~274

[20] Gerstein ES, Grisaenko EV, et al.Vascular endothelialgrowth factor and plasminogen activator in endometrialcarcinoma and hyperplasial.Vopr Onkol, 2003, 49 (6) :725~9

[21] Osmak M, Babic D, et al.Plasminogen activator inhibitortype 2:potential prognostic factor for endometrialcarcinoma[J].Neoplasma, 2001, 48 (6) :462~467

[22] Fredstorp-Liderbring M, et al.Urokinase plasminogenactivator and its inhibitor, PAI-1, in association withprogression-free survical in early stage endometrial cancer[J].Eur J Cancer, 2001, 37 (18) :2339~2348

[23] Nordengren J, et al.High tumor tissue concentration ofplasminogen activator inhibitor 2 (PAI-2) is an independentmarker for shorter progression-free survival in patients withearly stage endometrial cancer[J].Int J Cancer, 2002, 97 (3) :379~385

[24] Saito R, Nagushima M, Iwata M, et al.The concentrationof tissue plasminogin activator and urokinase in plasma andtissues of patients with ovarian and uterine tumots[J].ThrombRes, 1990, 58 (4) :355~366

[25] Koelbl H, Kirchheimer J, Tatra G, et al.Increasedplasma levels of urokinase-type plasminoge activator withendometrial and cervical cancer[J].Obster Gynecol, 1988, 72:252~255

[26] 贾海燕, 王洁义, 等.正常人静脉血流阻断后血浆组织型纤溶酶原激活剂含量、活性及其抑制物活性的变化[J].上海医科大学学报, 14 (5) :375~377 link1

[27] 陈卫昌, 严辉等.胃癌患者血清uPA测定及临床意义[J].ActaАсаdемiаеMedicine, 2001, 21 (4) :440~445 link1